23 Jul, 2026
According to Straits Research, the global growth hormone deficiency market size was valued at $4.89 billion in 2025 and is projected to grow from $5.1 billion in 2026 to $7.2 billion by 2034, registering a CAGR of 4.4% during the forecast period (2026–2034).
Human growth hormone, also known as somatotropin secreted by the pituitary gland, promotes cell growth, renewal and repair, reproduction, and metabolism, which are all essential for human development. Human growth hormones also contribute to regulating bodily fluids, the metabolism of sugar and fat, the growth of muscles and bones, and the healing of wounds. Additionally, it improves muscle strength and performance. Growth hormone deficit (GHD) is an uncommon condition in which the pituitary gland fails to produce enough growth hormone.
According to the March 2017 NCBI article, the estimated prevalence of GHD is roughly 2 to 3 per 10,000 people. GHD is caused by structural pituitary illness or cranial irradiation and occurs alongside other hypopituitarism symptoms. Adult-onset GHD is attributed to pituitary adenomas, followed by craniopharyngiomas, which account for around 57% of cases.
In addition, childhood-onset growth hormone deficiency (CO-GHD) is one of the complicated endocrine disorders that can have lifelong effects, beginning in childhood and lasting into maturity. Further, the most prevalent co-morbidities and symptoms of GHD in adults and children include obesity, diabetes, hypertension, cerebrovascular illness, cardiovascular disease, and liver disease. The expansion of the growth hormone deficiency market is anticipated to be driven by the rising prevalence of GH illness in children and adults.
The increased need for growth hormone therapy and lucrative growth potential has motivated industry participants to research and manufacture novel medications. For example, Novo Nordisk launched a Phase III trial of Somapacitan in March 2017. (NNC0195-0092). The drug is formulated to treat ADHD. The introduction of this new medication is likely to stimulate the growth hormone market soon.
The expanding popularity of e-commerce also permits a substantial development in online pharmacies, resulting in the widespread availability of pharmaceutical products. In July 2017, Amazon, a retail giant in the United States, entered the Middle Eastern market. Amazon purchased the Middle Eastern e-commerce company Souq.com to extend its product and service offerings. E-commerce distribution channels make for a sizable portion of the global growth hormone industry, creating chances for numerous GHD market participants.
Americas is the most significant shareholder in the global growth hormone deficiency market and is anticipated to grow at a CAGR of 4.60% during the forecast period. The growth hormone deficiency market in the Americas is expected to hold a substantial share due to the increasing prevalence of growth hormone deficiency and Turner syndrome, the accessibility of expensive hormonal therapy, and the region's well-established healthcare infrastructure. According to the Human Growth Foundation, more than 50,000 persons in the United States suffer from the growth hormone deficiency, and 6,000 new instances are recorded yearly. In addition, the increase in government support for the healthcare sector is projected to drive market expansion in this region.
Europe is estimated to grow at a CAGR of 4.52% over the forecast period. The European market for growth hormone insufficiency includes both Eastern and Western Europe. Western Europe consists of Germany, the United Kingdom, France, Italy, and Spain. Europe is anticipated to be the second-largest market for growth hormone insufficiency. This region's market expansion can be attributed to the increasing prevalence of growth hormone deficiency, the growing preference for growth hormones in treating idiopathic short stature (ISS), and increased government spending in the healthcare industry.
sales@straitsresearch.com